|
|
|
| Targeting Regulation of CHPT1 Gene Expression by miR-33 in Chicken (Gallus gallus) |
| SHAO Fang1, 2, *, WANG Xing-Guo2, 3, YU Jian-Feng2, LI Hui4, GU Zhi-Liang2, * |
1 The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou 213003, China;
2 School of Biology and Food Engineering, Changshu Institute of Technology, Changshu 215500, China;
3 Jiangsu Institute of Poultry Science, Yangzhou 225125, China;
4 College of Animal Science and Technology, Northeast Agricultural University, Harbin, 150030, China |
|
|
|
|
Abstract In addition to the regulation of lipid metabolism, miR-33 is also reported to be involved in glucose metabolism, inflammatory response, and cell cycle. However, the role of the chicken (Gallus gallus) miR-33 and its relationship with the predicted target gene choline phosphotransferase 1 (CHPT1) are still unclarified. The present study was conducted to investigate whether CHPT1 was the target gene of miR-33. The bioinformatics methods were used to predict the target genes of miR-33, and 378 genes from 3'-UTR database were predicted and CHPT1 gene was included. Then, the miR-33 overexpression vector and CHPT1 luciferase reporter vector were constructed and co-transfected into the mouse (Mus musculus) C2C12 myoblast cell, dual-luciferase reporter assay showed that the expression of luciferase reporter gene linked to the 3'-untranslated region of CHPT1 mRNA was down-regulated by miR-33 overexpression in C2C12 cells (P<0.01). Furthermore, the down-regulation was completely abolished when the predicted miR-33 target site in CHPT1 3'-UTR was mutated. Then mir-33 antagonists LNA (locked nucleic acid)-antimiR-33 was designed and synthetised, after transfecting chicken primary liver cells, the expression level of miR-33 decreased by 44%, while CHPT1 mRNA increased with a certain degree. By qRT-PCR, it was found that miR-33 highly expressed in muscular stomach and heart muscle, and the miR-33 expression in muscular stomach was significantly different from that in spleen, kidney, brain and glandular stomach (P<0.05), and very significantly different from that in liver and thigh muscle (P<0.01). In liver and abdomen fat tissue of 4 week lean and fat line chicken, miR-33 was significantly higher in the fat line than that in the lean line (P<0.05). The CHPT1 expression in the abdominal fat tissues was significantly higher in fat line chicken than that in lean line chicken (P<0.05). The above data indicate that miR-33 might play an important role in lipid metabolism in the chicken liver by negatively regulating the expression of CHPT1. The present study provides new clues for lipid synthesis.
|
|
Received: 13 April 2018
|
|
|
|
Corresponding Authors:
*, fuchenai@foxmail.com; zhilianggu88@hotmail.com
|
|
|
|
[1] Bernstein E, Caudy A A, Hammond S M, et al.2001. Role for a bidentate ribonuclease in the initiation step of RNA interference[J]. Nature, 409(6818): 363-366.
[2] Boumann H A, de Kruijff B, Heck A J, et al.2004. The selective utilization of substrates in vivo by the phosphatidylethanolamine and phosphatidylcholine biosynthetic enzymes Ept1p and Cpt1p in yeast[J]. FEBS letters, 569(1-3): 173-177.
[3] Cirera-Salinas D, Pauta M, Allen R M, et al.2012. Mir-33 regulates cell proliferation and cell cycle progression[J]. Cell cycle, 11(5): 922-933.
[4] Davalos A, Goedeke L, Smibert P, et al.2011. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling[J]. Proceedings of the National Academy of Sciences of the USA, 108(22): 9232-9237.
[5] Elmen J, Lindow M, Schutz S, et al.2008. LNA-mediated microRNA silencing in non-human primates[J]. Nature, 452(7189): 896-899.
[6] Elmen J, Lindow M, Silahtaroglu A, et al.2008. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver[J]. Nucleic Acids Research, 36(4): 1153-1162.
[7] Gerin I, Bommer G T, McCoin C S, et al.2010. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis[J]. American Journal of Physiology-Endocrinology and Metabolism, 299(2): E198-E206.
[8] Gerin I, Clerbaux L A, Haumont O, et al.2010. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation[J]. The Journal of Biological Chemistry, 285(44): 33652-33661.
[9] Heneghan H M, Miller N,Kerin MJ.2010. Role of microRNAs in obesity and the metabolic syndrome[J]. Obesity reviews : An official Journal of the International Association for the Study of Obesity, 11(5): 354-361.
[10] Hilton C, Neville M J, Karpe F.2013. MicroRNAs in adipose tissue: Their role in adipogenesis and obesity[J]. International Journal of Obesity, 37(3): 325-332.
[11] Hjelmstad R H, Bell R M.1987. Mutants of Saccharomyces cerevisiae defective in sn-1,2-diacylglycerol cholinephosphotransferase. Isolation, characterization, and cloning of the CPT1 gene[J]. The Journal of Biological Chemistry, 262(8): 3909-3917.
[12] Horie T, Ono K, Horiguchi M, et al.2010. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo[J]. Proceedings of the National Academy of Sciences of the USA, 107(40): 17321-17326.
[13] Hoekstra M, van der Sluis R J, Kuiper J, et al.2012. Nonalcoholic fatty liver disease is associated with an altered hepatocyte microRNA profile in LDL receptor knockout mice[J]. Journal of Nutritional Biochemistry, 23(6): 622-628.
[14] Iliopoulos D, Drosatos K, Hiyama Y, et al.2010. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism[J]. Journal of Lipid Research, 51(6): 1513-1523.
[15] Kent C.2005. Regulatory enzymes of phosphatidylcholine biosynthesis: A personal perspective[J]. Biochimica et Biophysica Acta, 1733(1): 53-66.
[16] Kim J, Yoon H, Ramirez CM, et al.2012. MiR-106b impairs cholesterol efflux and increases Abeta levels by repressing ABCA1 expression[J]. Experimental Neurology, 235(2): 476-483.
[17] Marquart T J, Allen R M, Ory D S, et al.2010. miR-33 links SREBP-2 induction to repression of sterol transporters[J]. Proceedings of the National Academy of Sciences of the USA, 107(27): 12228-12232.
[18] Poritsanos N J, Lew P S, Mizuno T M.2010. Relationship between blood glucose levels and hepatic Fto mRNA expression in mice[J]. Biochemical and Biophysical Research Communications, 400(4): 713-717.
[19] Rayner K J, Esau C C, Hussain F N, et al.2011. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides[J]. Nature, 478: 404-407.
[20] Rayner K J, Sheedy F J, Esau C C, et al.2011. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis[J]. The Journal of Clinical Investigation, 121(7): 2921-2931.
[21] Rayner K J, Suarez Y, Davalos A, et al .2010. MiR-33 contributes to the regulation of cholesterol homeostasis[J]. Science, 328(5985): 1570-1573.
[22] Sanchez-Pulido L, Andrade-Navarro M A.2007. The FTO (fat mass and obesity associated) gene codes for a novel member of the non-heme dioxygenase superfamily[J]. BMC Biochemistry, 8: 23.
[23] Shao F, Wang X G, Yu J F, et al.2014. Expression of miR-33 from an SREBF2 intron targets the FTO gene in the chicken[J]. PloS One, 9(3): e91236.
[24] Xie H, Sun L, Lodish H F.2009. Targeting microRNAs in obesity[J]. Expert Opinion on Therapeutic Targets, 13(10): 1227-1238. |
|
|
|
